1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Nicox SA.
  6. News
  7. Summary
    COX   FR0013018124

NICOX SA.

(COX)
  Report
Real-time Euronext Paris  -  05/20 04:10:20 am EDT
1.842 EUR   +0.33%
05/16Ophthalmology Group Nicox Appoints New CEO, Chairman
MT
05/16Nicox Announces a New Governance Structure
GL
05/16Nicox Announces a New Governance Structure
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Nicox: Half-year liquidity contract statement for NICOX

01/06/2022 | 01:30am EDT
Press Release
Nicox: Half-year liquidity contract statement for NICOX

January 6, 2022 – release at 7:30 am CET
Sophia Antipolis, France

Under the liquidity contract entered into between Nicox SA (Euronext Paris: FR0013018124, COX) and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31st 2021:

- 211,967 shares
- € 146,491.49

- Number of executions on buy side on semester: 786
    - Number of executions on sell side on semester: 728
    - Traded volume on buy side on semester: 387,737 shares for € 1,278,136.61
    - Traded volume on sell side on semester: 394,689 shares for € 1,304,467.12

As a reminder :

• the following resources appeared on the last half year statement on 30 June 2021 on the liquidity account:

     - 218,919 shares
     - € 128,032.29

     - Number of executions on buy side on semester: 1,594
     - Number of executions on sell side on semester: 1,298
     - Traded volume on buy side on semester: 978,682 shares for € 4,245,529.01
     - Traded volume on sell side on semester: 906,908 shares for € 3,977,929.37

• the following resources appeared on the liquidity account when the activity started:

     - 0 shares
     - € 500,000.00

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June
22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

About Nicox
Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets.

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com.
Analyst coverage


Bryan, Garnier & Co         Dylan van Haaften        Paris, France
Edison Investment Research        Pooya Hemami        London, UK
H.C. Wainwright & Co        Yi Chen        New York, U.S.
Kepler Cheuvreux        Damien Choplain        Paris, France
 
The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.
Contacts
Nicox
Gavin Spencer
Executive Vice President, Chief Business Officer
& Head of Corporate Development
T +33 (0)4 97 24 53 00
communications@nicox.com
Investors & Media
United States & Europe
LifeSci Advisors, LLC
Sandya von der Weid
T +41 78 680 05 38
svonderweid@lifesciadvisors.com
Media
France
LifeSci Advisors, LLC
Sophie Baumont
T +33 (0)6 27 74 74 49
sophie@lifesciadvisors.com
Forward-Looking Statements
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox’s business are presented in the 3rd chapter of the ‘Document d’enregistrement universel, rapport financier annuel et rapport de gestion 2020’ filed with the French Autorité des Marchés Financiers (AMF) on March 1, 2021 and in the 2nd chapter of the amendment to the “Document d’Enregistrement Universel, rapport financier annuel et rapport de gestion 2020” filed with the AMF on December 9, 2021 which are available on Nicox’s website (www.nicox.com).
Nicox S.A.
Drakkar 2
Bât D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99

 

 

Attachment

  • EN_Bilan semestriel 2021_Nicox PR_20220106_F1

© OMX, source GlobeNewswire - EU Press Releases

All news about NICOX SA.
05/16Ophthalmology Group Nicox Appoints New CEO, Chairman
MT
05/16Nicox Announces a New Governance Structure
GL
05/16Nicox Announces a New Governance Structure
AQ
05/16Nicox S.A. Announces Executive Changes
CI
05/04NICOX : 2022 Ordinary Shareholder Meeting
GL
05/04NICOX : 2022 Ordinary Shareholder Meeting
AQ
05/02NICOX AT ARVO 2022 : Presentation of clinical Phase 2 results on NCX 4251 and new non-clin..
GL
05/02NICOX AT ARVO 2022 : Presentation of clinical Phase 2 results on NCX 4251 and new non-clin..
AQ
04/28Nicox Reports 2021 Financial Results and First Quarter 2022 Financial Highlights and Pr..
AQ
04/11Nicox's NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucoma
AQ
More news
Financials
Sales 2022 9,03 M 9,56 M 9,56 M
Net income 2022 -20,3 M -21,5 M -21,5 M
Net cash 2022 2,20 M 2,33 M 2,33 M
P/E ratio 2022 -3,96x
Yield 2022 -
Capitalization 79,4 M 84,0 M 84,0 M
EV / Sales 2022 8,55x
EV / Sales 2023 6,84x
Nbr of Employees 33
Free-Float 89,6%
Chart NICOX SA.
Duration : Period :
Nicox SA. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NICOX SA.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 1,84 €
Average target price 11,50 €
Spread / Average Target 526%
EPS Revisions
Managers and Directors
Michele Garufi Chairman & Chief Executive Officer
Sandrine Gestin Vice President-Finance
José Boyer Head-Research & Development
Doug Hubatsch Chief Scientific Officer
Jean-François Labbé Independent Director
Sector and Competitors
1st jan.Capi. (M$)
NICOX SA.-28.14%84
MERCK KGAA-26.12%74 805
KYOWA KIRIN CO. LTD.-11.71%11 603
SK BIOPHARMACEUTICALS CO., LTD.-11.52%5 426
YUHAN CORPORATION-6.28%3 138
ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD.88.57%2 846